Technical Analysis for LGND - Ligand Pharmaceuticals Incorporated

Grade Last Price % Change Price Change
grade D 104.0 -0.66% -0.69
LGND closed down 0.66 percent on Friday, September 20, 2019, on 2.22 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical LGND trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Weak + Overbought Other 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Pocket Pivot Bullish Swing Setup -0.66%
Calm After Storm Range Contraction -0.66%
Upper Bollinger Band Walk Strength -0.66%
Crossed Above 50 DMA Bullish 4.76%
MACD Bullish Centerline Cross Bullish 4.76%

Older signals for LGND ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Ligand Pharmaceuticals Incorporated, a biotechnology company, engages in the acquisition and development of royalty revenue generating assets in the United States. The company's assets include PROMACTA, an oral thrombopoietin receptor agonist therapy for the treatment of adult patients with chronic immune thrombocytopenic purpura; Kyprolis for the treatment of multiple myeloma; AVINZA, a pain therapeutic; Viviant/Conbriza for the treatment of postmenopausal osteoporosis; Nexterone, an injectable formulation; and Viviant (bazedoxifene) for the treatment of postmenopausal osteoporosis. Its late-stage development programs comprise PROMACTA, which is in is in Phase II clinical studies for the treatment of oncology-related thrombocytopenia in patients with solid tumors, sarcoma, and Myelodysplastic Syndrome. The company's late-stage development programs also include Merck Captisol program that is in Phase III studies; Captisol-enabled Clopidogrel, which is in Phase III studies; RE-021 program, a dual acting receptor antagonist that is in various stages of development for indications of severe kidney diseases; Dinaciclib that is in Phase IIb/III adaptive clinical trials for the treatment of patients with refractory chronic lymphocytic leukemia; and Beta-Secretase Inhibitor, which is in Phase II/III studies for treating Alzheimer's disease. In addition, its late-stage development programs comprise Captisol-enabled Delafloxacin, a Phase III clinical trial product for the management of acute seizure disorder; and Captisol-enabled Delafloxacin that is in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections. The company has alliances with GlaxoSmithKline, Onyx Pharmaceuticals, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Lundbeck Inc., Eli Lilly and Co., Spectrum Pharmaceuticals, and The Medicines Company. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in La Jolla, California.
Biotechnology Pain Chemical Compounds Organic Compounds Solid Tumors Alzheimer's Disease Multiple Myeloma Chloroarenes Myelodysplastic Syndrome Clinical Trial Product Phenols Skin And Skin Structure Infections Sarcoma Carboxylic Acids Selective Estrogen Receptor Modulators
Is LGND a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 278.62
52 Week Low 85.0
Average Volume 443,164
200-Day Moving Average 115.9958
50-Day Moving Average 98.1014
20-Day Moving Average 93.6425
10-Day Moving Average 97.203
Average True Range 4.6648
ADX 29.38
+DI 29.0744
-DI 14.5347
Chandelier Exit (Long, 3 ATRs ) 93.6756
Chandelier Exit (Short, 3 ATRs ) 98.9944
Upper Bollinger Band 104.7944
Lower Bollinger Band 82.4906
Percent B (%b) 0.96
BandWidth 23.818031
MACD Line 1.5434
MACD Signal Line -0.4208
MACD Histogram 1.9642
Fundamentals Value
Market Cap 2.19 Billion
Num Shares 21.1 Million
EPS 0.41
Price-to-Earnings (P/E) Ratio 253.66
Price-to-Sales 25.74
Price-to-Book 7.36
PEG Ratio 1.53
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 110.87
Resistance 3 (R3) 111.33 109.50 109.72
Resistance 2 (R2) 109.50 107.75 109.27 109.34
Resistance 1 (R1) 106.75 106.67 105.84 106.29 108.96
Pivot Point 104.92 104.92 104.46 104.69 104.92
Support 1 (S1) 102.17 103.17 101.26 101.71 99.04
Support 2 (S2) 100.34 102.09 100.11 98.66
Support 3 (S3) 97.60 100.34 98.28
Support 4 (S4) 97.13